DelveInsight has launched a new report on Relapsed/Refractory Acute Myeloid Leukemia Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s ‘Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Request for :- RAML free sample page
Epidemiology
The Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Reports Highlights
Report key facts:-
1. The incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people age
2. According to a cross-national study using US and England data, found that the overall risk of mortality for AML was 23% lower in England compared to that in the US. However, survival difference was similar in subgroups of sex and age at diagnosis. (Xie et al.)
Key Assessments
Table of Contents
1. Key Insights
2. Executive Summary of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
3. Relapsed/Refractory Acute Myeloid Leukemia (R/R AML): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treatment and Management
6.2. Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Why should you buy this report?
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/